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Abstract.  Rotaviruses are icosahedral particles that as- 
semble in the lumen of the endoplasmic reticulum 
(ER).  The viral glycoprotein, VP7,  is also directed 
into this compartment and is retained for assembly 
onto the surface of viral cores.  VP7  is therefore a  resi- 
dent ER glycoprotein with a  luminal orientation. 
The VP7 gene possesses two potential in-frame initi- 
ation codons, each preceding a  hydrophobic domain. 
Mature VP7 is derived from a  precursor by cleavage 
but the site of cleavage has not been determined be- 
cause viral VP7 has a blocked amino terminus.  Using 
site-directed mutagenesis of the gene and in vitro tran- 
scription and translation systems, we have investigated 
the synthesis and processing of the primary products 
synthesized from each initiation codon.  Proteins trans- 
lated from either codon were processed in vitro to 
yield products indistinguishable in size.  The primary 
translation products therefore appeared to be cleaved at 
the same site.  The site was located empirically be- 
tween Ala50 and Gin51 and mutation of the gene to 
convert Ala50~Val prevented processing.  Amino- 
terminal sequence analyses of proteins synthesized in 
vitro, and characterization of an amino-terminal frag- 
ment of VP7 purified from virus unequivocally estab- 
lished Gin51  as the amino-terminal residue.  Pyroglu- 
tamic acid was tentatively identified as the blocking 
group. 
Processing of VP7 therefore removes both amino- 
terminal hydrophobic domains from the protein.  Some 
other mechanism not requiring the presence of these 
hydrophobic sequences must account for the retention 
of this novel glycoprotein in the ER. 
OTAVIRUSES are icosahedral viruses possessing a dis- 
tinctive morphogenetic pathway (11). The inner core 
of the virus assembles in the cytoplasm in viroplas- 
mic inclusions and buds through the membrane of the en- 
doplasmic reticulum (ER), i becoming enveloped in the pro- 
cess.  The membrane envelope is later lost by an unknown 
mechanism and the outer proteins are assembled on the sur- 
face of the core (7).  Glycoprotein VPT, the major serotype 
antigen of rotaviruses,  is directed to the lumen of the ER 
where it is retained (20), apparently as an integral membrane 
protein (10). The incomplete virus particles therefore proba- 
bly acquire VP7 either during or after the budding process. 
The VP7 gene has now been cloned and sequenced for five 
serotypes of animal and human rotaviruses (8, 9).  In each 
case the nucleotide sequence predicts an open reading frame 
of 326 amino acids beginning with an initiation codon with 
a  weak consensus sequence  (12, 13). A  second,  in-frame 
initiation codon with a  strong consensus sequence lies 30 
codons downstream. Each initiation codon precedes a region 
of hydrophobic amino acids which is able to direct VP7 to 
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1. Abbreviations used in this paper: endo H, endoglycosidase H; ER, en- 
doplasmic reticulum. 
the ER (27). During translocation VP7 is cleaved (6), but the 
exact cleavage site was not identified because the viral pro- 
tein had a  blocked amino terminus (1,  15). Depending on 
where VP7 translation begins and where the protein is cleaved 
during translocation, the gene could potentially produce two 
proteins, one perhaps in minor amount, which might have 
subtly different functions. In fact, two species of VP7 have 
been reported to exist in virus particles  (4).  Multiple in- 
frame initiation codons that generate distinct polypeptides 
have also been observed in other viruses (12). 
Most proteins destined for export from the cell are translo- 
cated across the ER membrane with concomitant cleavage of 
the amino-terminal signal sequence (26).  In some cases this 
does not occur, resulting in the formation of a class II mem- 
brane protein which is retained in the membrane via a com- 
bined signal/anchor domain (28).  VP7  would thus be re- 
garded  as  a  class  II protein  if processing  preserved  the 
second hydrophobic domain and it served as a membrane an- 
chor. However, because the virus matures in the lumen of the 
ER and in its final form is nonenveloped, it might be ex- 
pected that VP7 could be processed to remove both hydro- 
phobic domains before assembly on the surface of the virus. 
A  series  of empirical rules to predict cleavage  sites in 
membrane proteins has been proposed (24, 25). When these 
are applied to VP7 (Fig.  1) a cleavage  site after residue 50 
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Figure  1.  Location  of possible  signal  peptidase 
cleavage sites within the amino-terminal 100 resi- 
dues of VP7 using empirical rules formulated from 
the study of known cleavage sites by van Heijne 
(25) and a computer program written by C. Buc- 
holtz. The vertical axis gives the score calculated 
by summing the natural logarithms of the weight- 
matrices for each residue (25). The horizontal axis 
shows  amino acid  numbers  in the open  reading 
frame. 
is identified.  This predicts  that mature  VP7  would possess 
amino-terminal  glutamine  and  lack  both  hydrophobic  do- 
mains. The availability of a cloned copy of the VP7 gene (2) 
and the relative ease of constructing mutations has led us to 
investigate the use of the cleavage site by site-directed muta- 
genesis. This approach,  coupled with partial amino terminal 
sequence analysis of the amino-terminal region of VP7 has 
enabled us to unequivocally identify the cleavage site as resi- 
due  50. 
Materials and Methods 
Mutation and Manipulation of VP7 Genes 
A full-length cloned copy of the VP7 gene (i.e.,  segment 9 of SAID and 
mutants of the VP7 gene, 1-14 and 27S (Fig. 2), were inserted into the SV40 
expression vector pJCll9 (20, 27). Insertion of the VP7 gene and its deletion 
mutants into the Bluescribe vector (Stratagene, San Diego, CA), and the 
construction of further point mutations Z, S, and T (Fig. 2, Table I) has been 
described  (20, 27). 
Additional mutations were introduced into the VP7 gene as follows: 
(a) The M mutation, which converted the second AUG codon to UUG 
(Fig. 2, Table I), was introduced by a strategy similar to that described for 
the T mutation (27). Briefly, the 5'-terminal  BamHI fragment from the Z 
variant of the gene was subcloned into M13mpll and single-stranded tem- 
plate DNA was prepared. An oligonucleotide (19-mer) corresponding to the 
coding strand of the VP7 gene was synthesized (DNA synthesizer, model 
380A, Applied Biosystems, Inc., Foster City, CA) with a single-base mis- 
match at base  136 (Table I). The oligonucleotide was elongated by DNA 
polymerase (Klenow) in the presence of T4 DNA ligase using the single- 
stranded MI3 DNA as template (17). Mutant colonies were identified by 
differential hybridization of the radiolabeled oligonucleotide at a tempera- 
ture near its Tm and the presence of the mutation was confirmed by nucleo- 
tide sequencing.  Double-stranded  DNA was prepared,  the 5' XhoI-Ncol 
•230-bp  fragment purified and the modified sequences incorporated into 
the VP7 gene in the SV40 vector pJCll9 by three-fragment ligation (20, 27). 
(b) Mutation C3 (Fig. 2, Table I), designed to inhibit potential cleavage 
by signal peptidase,  was a point mutation in VP7 changing codon GCA 
(Ala50) to GTA (Val). The mutation was introduced independently into both 
the full-length VP7 gene 9ZMT,  and the deletion mutant  1-14T (Fig. 2). 
Single-stranded DNA from these genes in the Bluescribe M13+ vector was 
prepared using protocols recommended by the supplier and a D-base oligo- 
nucleotide of plus-stranded sense, with a mismatch at position 197, was used 
to introduce the mutation. 
Transfection of  DNA and Detection of 
Expressed Proteins 
Transfection of plasmid DNAs into cone outer segment (COS) cells, recov- 
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Figure 2. Partial maps for wild-type and variant 
VP7 genes and proteins. The top of the figure 
shows the position of the first three  in-frame 
initiation codons and the location of mutations 
Z, S, M,  C3, and T relative to key restriction 
endonuclease sites within the gene (B, BamHI; 
N,  NcoI;  X,  XhoI).  The  amino-terminal  74 
residues of wild-type (WT) VP7 and mutations 
in them are shown using the single-letter amino 
acid code. Hydrophobic regions H1 and H2 are 
overlined.  For the  deletion  mutants  27S  and 
1-14, heavy lines indicate amino acid sequence 
translated  from the  gene.  Former coding  re- 
gions not translated because of an upstream ter- 
minator (*, T/S) or the deletion of an initiation 
codon (1-14) are shown as thin lines. Regions of 
DNA deleted are shown  as the thinnest  line. 
CHO,  carbohydrate  attached at Ash69. 
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Mutation*  Codon(s) altered  Effect 
Z  TTAATGTAT  >  ATAATGGAT 
S  TAC  >  TAA/G 
M  ATG >  TTG 
C3  GCA  >  GTA 
T  AAT >  GAT 
"Weak" to "strong" first initiation codon plus Tyr2  changed to Asp* 
Tyr6 to STOP;  t 
Second  initiation codon (Met30)  to Leuw 
Ala50 changed to Val to remove potential  signal peptidase  cleavage 
sitew 
Asn69 -" Asp,  removes the only N-linkod glycosylation site in 
SAIl  VP7* 
* The wild-type VP7 protein ofSAl 1 virus is encoded in genomic segment 9. Multiple mutations in this gene have been designated in the text by the use of multiple 
letters (e.g., 9ZMT, Fig. 2, contains three separate mutations in the gene 9 nucleotide sequence). 
-~ Whitfeld et al. (27). 
w This work. 
ery of expressed VP7 proteins by immunoprecipitation, and their analysis 
by polyacrylarnide gel electrophoresis and autoradiography were carried out 
as previously described (20, 27). 
In Vitro Transcription and Translation 
The wild-type VP7 gene and the derived mutant genes were excised from 
pJC119 with XhoI and subcloned into the SalI site of the Bluescribe M13+ 
vector under the control of the T7 transcriptional promoter. RNA transcripts 
were synthesized for 1 h at 37~  as directed by the supplier, except that 
m7G(5')ppp(5')  G  (Pharmacia  Fine Chemicals,  Uppsala,  Sweden)  (500 
IxM) was included in the reaction and the GTP concentration was reduced 
to 10 ~tM, The resulting mRNAs were translated using rabbit reticutocyte 
lysates (Promega Biotec, Madison, WI) in the presence of [-~SS]methionine 
(Amersham [Aust.], North Ryde, NSW) and canine pancreatic microsomes 
(Amersham [Aust.]) when appropriate (27). Conditions for digesting trans- 
lation products with endoglycnsidase H (endo H) or trypsin and the analysis 
of proteins by gel electrophoresis have been described (4,  14). 
Growth of  SAll Rotavirus 
SAIl  rotavirus was propagated and radiotabeled with [35Slmethionine or 
[3H]mannose in MAIIM cells and purified by equilibrium centrifugation on 
a CsCl gradient (23). 
Amino-terminal Sequence Analysis of  Proteins 
Polypeptides  translated  and  radiolabeled  in  vitro  or  [35S]methionine- 
labeled viral VP7, were separated by electrophoresis on polyacrylamide gels 
and purified by electroelution (22). The eluted protein was transferred to 
a siliconized Eppendorf tube and precipitated with 9 vol of methanol over- 
night at  -20~  Acetylated BSA (2 ~g/ml) was added as protein carrier. 
The precipitated protein was resuspended in 0.1% SDS (50 ~tl) and submit- 
ted to Edman degradation using a microsequencer (model 470A, Applied 
Biosystems, Inc.). 
To remove putative pyroglutamic acid from the amino terminus, eluted 
proteins were resuspended in deblocking buffer (50 Ixl) (19), pyroglutamate 
aminopeptidase (5 U, Sigma Chemical Co., St. Louis, MO) was added, and 
the sample was incubated at room temperature for 2  h. A  further 5 U  of 
enzyme was then added and incubation was continued for a further 2 h. The 
protein was precipitated and resuspended in 0.1%  SDS (50 I~1) for Edman 
degradation.  Radioactivity released during each cycle was determined by" 
liquid scintillation counting. 
Results 
Identification of  Proteins Translated  from each 
Initiation Codon 
The putative product of the first initiation codon is very 
poorly translated in rabbit reticulocyte lysates (2, 4), pre- 
sumably because of the presence of a  weak consensus se- 
quence surrounding the codon (13). To enable the full-length 
protein to be more easily characterized, and to improve ex- 
pression of VP7 from the first ATG site, the sequence of the 
gene was modified from 5'..TTAATGT..3' to ..ATAATGG.. 
(Z mutation, Fig. 2, Table I) (27). Translation from the first 
AUG  codon  increased  an  estimated three-  to  fivefold in 
reticulocyte lysates (data not shown). 
The identity of VP7 proteins translated from the two po- 
tential initiation codons in the gene and a  third in-frame 
codon at position 63 (Fig. 2) was determined by translation 
of RNA transcripts derived from the full-length gene 9 and 
the two deletion mutants, 1-14 and 27S. With these transcripts 
protein synthesis should initiate at the first, second, and third 
AUG codons, respectively (Fig. 2). The T mutation (Fig. 2, 
Table I), which removes the glycosylation site, was also in- 
corporated into some genes so that the size of the processed 
polypeptides could later be examined in the absence of any 
size change due to glycosylation. The full-length gene 9ZT 
yielded four proteins in the size range expected for VP7 (Fig. 
3a,  lane 1).  The smallest of these was usually faint. The 
bands were all VP7-related in that none of them were seen 
when no RNA was added to the lysate and all were immuno- 
precipitated with antiserum directed against VP7 (data not 
shown). Only the largest product was specific to the first ini- 
tiation codon because the middle two proteins were synthe- 
sized in response to 1-14T RNA (lane 5) and the smallest was 
made in the presence of 27S RNA (lane 7). Inasmuch as both 
1-14T proteins disappeared when the M mutation was incor- 
porated in gene 9ZMT (lane 3), clearly they were translated 
from the second initiation codon. The reason for the synthe- 
sis of  two protein products from this codon is not clear. How- 
ever,  the partial amino-terminal sequence of each protein 
deduced by Edman degradation of [3H]isoleucine-labeled 
proteins was identical, beginning as expected at Met30 (data 
not shown). Further, transcripts derived from a 1-14 gene cut 
at an AccI site 79 bases from the stop codon, encoded two 
similar, but shorter proteins (data not shown),  suggesting 
that premature termination of translation does not account 
for their synthesis. In summary, transcripts from various mu- 
tated VP7 genes were translated in reticulocyte lysates to 
identify proteins specific for the first, second, and third in- 
frame initiation codons. 
Cleavage of  Proteins Derived  from Each 
Initiation Codon 
To determine whether proteins translated from each AUG 
Stirzaker et al. Processing and Retention of Rotavirus VP7  2899 codon could be transported across membranes and processed, 
canine pancreatic microsomes were added to the translation 
reactions. Entry of proteins into the microsomes was moni- 
tored by their resistance to digestion with exogenous trypsin. 
The size of mutant protein 27S  (translated from the third 
AUG) was unaffected by the addition of microsomes (Fig. 3, 
top, lanes 7 and 8), and the protein was sensitive to trypsin 
(27), indicating that it lacked the ability to cross the micro- 
somal membrane. In contrast, the 9ZMT and 1-14T proteins 
(Fig. 3, top, lanes 3 and 5) translated from the first and sec- 
ond AUG codons, respectively, were processed in the pres- 
ence of microsomes to a lower molecular mass product of  the 
same apparent size (Fig. 3, top, lanes 4 and 6). This result 
was  confirmed using  gene 9ZT,  which produced proteins 
from each AUG; only one new protein appeared when mi- 
crosomes were added (Fig.  3,  top, lane 2).  These micro- 
some-processed products were also tested for their resistance 
to trypsin digestion. In the absence of microsomes, the 9ZMT 
and  1-14T proteins were trypsin-sensitive (Fig.  3,  bottom, 
lanes 3 and 7). However, the same proteins produced in the 
presence of microsomes  were  resistant  to  digestion  with 
trypsin (Fig. 3, bottom,  lanes 4 and 8) indicating that they 
had crossed the microsomal membrane. 
Similar experiments were performed to examine the pro- 
cessing of proteins 9Z, 9ZM, and 1-14 that lacked the T mu- 
tation and therefore could be glycosylated. Despite the varia- 
tion in the size of the precursor proteins translated in the 
absence of microsomes (Fig. 4, left, lanes 3, 9, and 12), the 
glycosylated proteins produced in  the presence of micro- 
somes were identical in size (lanes 4, 8, and//) and appeared 
to  comigrate  with  glycosylated VP7  immunoprecipitated 
from SAil-infected MA104  cells  (lane 2).  After digestion 
with endo H, the resulting unglycosylated polypeptides were 
also identical in size (lanes 5, 7, and 10) and comigrated with 
the major species of VP7 present in endo H-treated proteins 
immunoprecipitated from SAil-infected ceils (lane 6). The 
three mutant proteins and VP7 from purified virus were also 
compared after digestion with endo H. Virus yielded a major 
band of similar size to the processed forms of the three in 
vitro products, but two minor viral bands were also present 
(Fig. 4, right, lanes 3, 4, and 5 vs.  7). The small difference 
in migration of the major viral protein relative to the mutant 
proteins (lanes 3-5) suggests that it may differ in some subtle 
way from the major protein in virus-infected cells which ap- 
peared to comigrate with the proteins produced in vitro (Fig. 
4, left, lane 6 vs.  lanes 5,  7, and 10).  Because microsome- 
dependent cleavage of the VP7 proteins initiated at the first 
and second AUG codons appears to produce a single protein, 
cleavage presumably occurs at a site common to both pro- 
teins,  i.e.,  downstream  of the  second  Met  and  probably 
downstream of the H2 region (Fig. 2). 
Identification of the Major Cleavage Site in VP7 
Empirical rules for predicting signal peptide cleavage sites 
in membrane proteins have been formulated from data accu- 
mulated for known cleavage events (24, 25) and these were 
used to examine VP7. Although residue 50 was predicted as 
the most likely cleavage site (Fig.  1), a previous study (4) 
suggested that cleavage occurred at a site between the two hy- 
drophobic domains H1 and H2; two low-probability cleavage 
sites after residues 25  and 27 are predicted in this  region 
Figure 3. Identification of proteins translated from each initiation 
codon and their processing by microsomes. Genes 9ZT, 9ZMT, 
1-14T, and 27S were inserted into the Bluescribe MI3+ vector and 
transcribed using T7 RNA polymerase. RNAs were translated in 
rabbit reticulocyte lysates using [35S]methionine (top) in the pres- 
ence or absence of canine pancreatic microsomes (M) and (bottom) 
treated with trypsin (T) as indicated. Proteins analyzed on 10% 
polyacrylamide gels were detected by autoradiography. The un- 
processed (I>) and processed (l~) product specific to each initiation 
codon is indicated in each case. The trypsin-resistant proteins are 
indicated (>). 
(Fig. 1). Because Pro at certain positions in cleavage sites is 
particularly unfavorable (24), site-directed mutagenesis was 
used to introduce Pro at residues 23, 25, or 27. The respective 
genes were inserted into the SV40 expression vector pJCll9 
and transfected into COS cells in the presence of tunicamycin 
so that the size of the polypeptides produced could be as- 
sessed. In earlier work it was observed that failure to cleave 
the H1 hydrophobic domain resulted in an increase in the size 
of the protein (27).  However, none of these mutations af- 
fected the size of VP7 suggesting that cleavage had still oc- 
curred  in  each  case  (data  not  shown).  Similarly,  protein 
9ZMT carrying an additional Ser--~Pro change at position 25 
was also cleaved by microsomes in vitro (data not shown), 
The Journal of Cell Biology, Volume 105,  1987  2900 Figure 4. Comparison of VP7 proteins synthesized in vitro with VP7 present in (leJ~) SAIl rotavirus-infected  cells and (right) purified virus. 
Genes 9Z, 9ZM, and 1-14 in the Bluescribe vector were transcribed using T7 RNA polymerase and the RNAs translated in reticulocyte 
lysates in the presence and absence of microsomes (M). Samples were treated (+) with endo H (H) or not treated (-) as indicated. Proteins 
were immunoprecipitated from rotavirus-infected MA104 cells (IC) and similarly treated with endo H (lane 6). (V) SAIl viral proteins. 
In vitro synthesized primary (1>), glycosylated (1~), and endo H-treated  products (>) are indicated. In left panel, lane 1 contains SA11 
VP7 (38 kD) and 46- and 30-kD proteins as markers. 
despite the fact that this mutation was designed to prevent 
cleavage at both sites (24, 25). 
The most favorable cleavage site Ala50~Gln51  was there- 
fore changed to Val50$Gln51  (C3 mutation, Fig. 2, Table I), 
based on the observation that Val in the -1 position was also 
unfavorable for cleavage (24, 25) and had prevented cleav- 
age of another mutant in  vitro (27).  RNAs transcribed in 
vitro from 9ZMTC3 and 1-14TC3 were translated in the pres- 
ence and absence of microsomes and the products compared 
with those from the equivalent genes lacking the C3 muta- 
tion. Clearly this mutation (Ala~Val) inhibited microsome- 
dependent processing of the protein derived from the first 
AUG codon (Fig. 5,  left,  compare lanes 1 vs.  2  with 5  vs. 
6). The sensitivity of the proteins to trypsin digestion in the 
absence of microsomes (lanes 3 and 7) and their resistance 
to trypsin when microsomes were added (lanes 4 and 8) indi- 
cated that although the C3 mutation prevented processing of 
this polypeptide it did not prevent its entry into microsomes. 
Similarly, the C3 mutation affected the processing of 1-14T 
translated from the second AUG (Fig. 5, right). In this case, 
the Ala~Val change did not completely prevent processing 
but resulted in the appearance of one, and perhaps two new 
products which were slightly smaller than processed 1-14T 
(compare lanes 2  and 6) and resistant to trypsin digestion 
when microsomes were present (Fig. 5, right, lanes 4 and 8). 
This suggested that when the primary cleavage site for signal 
peptidase was eliminated, a  secondary, less favorable (un- 
predicted) site(s) was used. This alternative site(s) may also 
have been used in processing protein 9ZMTC3 in that similar 
trypsin-resistant bands were present in minor amounts in the 
presence of microsomes (Fig. 5,  left,  lane 8). 
Determination of the Partial Amino-terminal 
Sequence of VP7 
We attempted to obtain amino-terminal sequence data for 
VP7 purified from virus but found the protein to be blocked, 
confirming the observation of other workers  (1,  15). The 
putative cleavage site  identified above predicts an amino- 
terminal glutamine residue for VP7 (Fig. 2), suggesting that 
the blocking group could be pyroglutamic acid. VP7 poly- 
peptides  translated  and  processed in  vitro were therefore 
Figure 5.  Effect of the C3 mutation on 
cleavage of nonglycosylated  proteins trans- 
lated from the first and second initiation 
codons.  Genes  9ZMT  and  9ZMTC3 
(leJ~) and 1-14T  and 1-14TC3  (right) were 
transcribed  in  the  Bluescribe  system, 
translated in reticulocyte lysates in the 
presence  and  absence  of microsomes 
(M), and treated with trypsin (T) as in- 
dicated.  The  unprocessed  (1>), pro- 
cessed (I~), and trypsin resistant prod- 
ucts (>) are indicated in each case. 
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Figure 6.  Partial amino-terminal sequence analysis of viral VP7 
proteins  and  in  vitro-translated  1-14 protein. [3sS]methionine- 
labeled viral VP7 proteins and 1-14 translated in vitro were sepa- 
rated by polyacrylamide  gel electrophoresis and located by autora- 
diography. The proteins were excised, recovered  by electroelntion, 
and submitted  to Edman degradation (A, C) before and (B, D) after 
digestion with pyroglutamate aminopeptidase. Radioactivity re- 
leased at each cycle was monitored by liquid scintillation counting. 
In samples A-D there were 19,300, 35,000, 100,000, and 300,000 
cpm of [35S]methionine  eluted from gels for analysis, respectively. 
There are 10 Met residues in VP7. 
purified by gel electrophoresis and electroelution and sub- 
jected to F_aiman  degradation before and after treatment with 
pyroglutamate aminopeptidase. Similar results were obtained 
for  analysis of [35S]methionine-labeled  proteins  1-14 and 
9ZM as well as nonglycosylated proteins 9ZMT and 1-14T 
(data not shown). In the absence of enzyme treatment no 
significant amount of radioactivity was released during 16 
cycles of  Edman degradation, except for cycle one (Fig. 6 C). 
This was not observed for 9ZMT (data not shown) and was 
probably  due to  contaminating, unprocessed  1-14 protein 
which had amino-terminal methionine (see  above).  After 
digestion with enzyme, which removes the blocked terminal 
residue, radioactivity was released at cycle 12 (Fig. 6 D), 
precisely the result expected if Gln51 were the amino-ter- 
minal residue in VP7. The result for 9ZMT was confirmed by 
analysis of [3H]isoleucine-labeled  protein (data not shown). 
The [35S]methionine-labeled  VP7 proteins derived from 
purified virus (Fig. 4,  right,  lane 6) were also analyzed. 
Without enzyme digestion, some radioactivity was repro- 
ducibly released at cycles 14 and 15 (Fig. 6 A). However, af- 
ter enzyme treatment, most radioactivity was again released 
at cycle 12 (Fig. 6 B), indicating that Gln51  was also the 
amino-terminal residue in viral VP7. 
To further confirm that cleavage occurred between Ala50 
and Gin51,  the amino-terminal glycopeptide of [3H]man- 
nose-labeled VP7 isolated from purified virus was released 
by digestion with Staphylococcus  aureus  V8 protease and 
isolated by HPLC. Such digestion of viral VP7 was expected 
to produce a peptide corresponding to amino acids Gln51- 
Glu74  (Fig.  2).  However three peaks of [3H]marmose-la- 
beled material were recovered and these were subjected to 
amino acid analysis. The composition of one peak closely 
agreed with that expected for the amino-terminal peptide 
(data not shown). The elution pattern and amino acid compo- 
sitions of the other two peaks  suggested that these  were 
shorter, related peptides, although their origin is unclear. 
Discussion 
Two in-frame initiation codons are conserved in all rotavirus 
VP7 genes so far sequenced and therefore the gene is poten- 
tially bicistronic (8, 9). We have identified proteins encoded 
from each possible initiation codon in the SAIl VP7 gene 
and examined their processing in vitro. Our results indicated 
that although the primary products translated from these 
codons were clearly distinct, the proteins cleaved and glyco- 
sylated by microsomes were indistinguishable in size.  The 
processed proteins also migrated at a rate very similar to that 
of a polypeptide(s) present in rotavirus-infected cells. 
A potential cleavage site downstream of the H2 region in 
VP7 (Fig. 2) was identified by scanning the amino acid se- 
quence using rules compiled from cleavage of other signal 
peptides (24, 25). Through the introduction of a point muta- 
tion at this site, cleavage was largely eliminated and the use 
of the site was confirmed directly by partial amino-terminal 
sequence analysis. Radiolabeled VP7 proteins synthesized in 
vitro and the mixture of viral VP7 proteins yielded similar 
amino-terminal sequence profiles (Fig. 6). The determina- 
tion of each partial sequence largely depended upon diges- 
tion of the proteins with pyroglutamate aminopeptidase. The 
amino acid composition of the amino-terminal glycopeptide 
purified from viral VP7  also  supported  the  site directed 
mutagenesis data. Collectively the results indicated that pro- 
cessing in vivo and in vitro occurred in the same way, the 
major cleavage site lying between Ala50 and Gln51 (Fig. 2). 
This location contrasts with that proposed in another report 
in which it was suggested that processing occurred between 
the H1 and H2 domains (4). Our results demonstrate that nei- 
ther HI  nor H2 are present in the mature form(s) of the 
protein. 
Although Gin51 is the major amino terminus of VP7, there 
were also indications that the protein may have a "ragged" 
end, consistent with the presence of multiple protein species 
in the virus (Fig. 4, right, lanes 6 and 7). In that only one 
methionine residue occurs near the proposed amino termi- 
nus (Met63,  Fig. 2), the release of small but reproducible 
amounts of radioactivity at cycles 14 and 15 during Edman 
degradation (Fig. 6 A) suggested that the minor species may 
have unblocked amino termini beginning with Arg49 and 
Ala50.  Similar results were also obtained for the analysis of 
processed proteins 9ZMT and 1-14T (data not shown) which 
were also heterogeneous (e.g. Fig. 5, right, lanes 2 and 4). 
We interpret these  data cautiously, however,  because  the 
composition of two glycopeptides purified from virus was 
more consistent with the loss of residues Gln51-Gly54  from 
the amino terminus. However, for the latter result we cannot 
rule out the possibility that partial, inappropriate cleavage by 
V8 protease produced these peptides, although we consider 
this to be unlikely. 
The major cleavage site producing amino-terminal Gln ap- 
pears to be a typical substrate for signal peptidase (Fig.  1) 
(24, 25) and is conserved in all VP7 serotypes (8, 9). How- 
ever, cleavage by signal peptidase to produce amino-terminal 
Arg49 or Ala50 is much less likely (25) and these residues 
are not conserved in other VP7 proteins (8, 9). In the absence 
of the primary cleavage site in 1-14TC3, processing at a sec- 
ondary site was observed.  Recent data show that this oc- 
curred at Gly54 and to a lesser extent at Asn52, generating 
amino-terminal Ile and Tyr (Fig. 2) (Stirzaker, S. C., unpub- 
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by the computer program (Fig.  1) (25). Cleavage at an alter- 
native site in yeast invertase was also observed after the in- 
troduction of an Ala-'Val mutation in the  -1  position (21). 
Inasmuch as we do not fully understand the origin of the mi- 
nor proteins which may have amino-termini other than Gin, 
we do not exclude the possibility that VP7 processing may 
lack  fidelity,  or involve an enzyme other than signal pep- 
tidase. 
Because the processed products translated from each AUG 
are  the  same,  apparently  the  first  initiation codon  is  not 
needed to produce VP7. This raises the question of why the 
codon is conserved in all the VP7 genes so far sequenced. 
There  are two obvious alternative explanations.  First,  the 
codon  is  conserved  because  of some  requirement  for  se- 
quence conservation at the level of the RNA.  The six VP7 
gene sequences available show very high homology for the 
first '~80 nucleotides and bases 37-72 (which include the first 
AUG) are identical except for a single base change in one 
gene (8). Secondly, the codon may be used in vivo to produce 
low levels of a protein with a subtly different property, e.g., 
in its ability to interact with a membrane. Although the rela- 
tive usage of each initiation codon in the infected cell is un- 
known, the simplest interpretation of the data is that VP7 is 
produced principally via the second initiation codon and sec- 
ond signal peptide region, and then cleaved between Ala50 
and Gln51. 
The principal phenomenon that must be explained in the 
light of the proposed cleavage site is the location of VP7 in 
the cell. Immunofluorescence studies using transfected cells 
(20) and analysis of the carbohydrate attached to VP7  (3) 
both indicate that the protein is  not transported along the 
normal secretory pathway of the cell. Rather, VP7 inherently 
locates in the ER for subsequent assembly onto viral cores 
during infection.  Further,  after a  10-min pulse-labeling of 
proteins in the infected cell, very little uncleaved VP7 is de- 
tectable (5) suggesting that slow cleavage, akin to that seen 
for a mutant of yeast invertase (21), does not provide transient 
anchoring. However, VP7 does remain anchored after pro- 
cessing (10) and our data unequivocally show that cleavage 
occurs after Ala50,  removing both of the hydrophobic do- 
mains. Clearly, therefore, only residues distal to residue 50 
can be involved in retaining VP7  in the ER.  Recently the 
tetrapeptide Lys-Asp-Glu-Leu has been proposed as a target- 
ing signal for luminal ER proteins (16).  However,  this se- 
quence is not present in VP7. The mechanism by which VP7 
is retained in the ER is under further investigation. 
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